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Abstract: Macrocyclic trichothecenes, mycotoxins produced by Stachybotrys chartarum, 
have been implicated in adverse reactions in individuals exposed to mold-contaminated 
environments. Cellular and humoral immune responses and the presence of trichothecenes 
were evaluated in patients with mold-related health complaints. Patients underwent history, 
physical examination, skin prick/puncture tests with mold extracts, immunological 
evaluations and their sera were analyzed for trichothecenes. T-cell proliferation, 
macrocyclic trichothecenes, and mold specific IgG and IgA levels were not significantly 
different than controls; however 70% of the patients had positive skin tests to molds. Thus, 
IgE mediated or other non-immune mechanisms could be the cause of their symptoms. 
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1. Introduction 
The “mold related illness” (MRI) is a controversial condition consisting of primarily non-specific 
symptoms such as headache, rhinorrhea, fatigue, memory loss, and eye irritation [1–6]. Although 
inhalation of high concentrations of mold spores has been reported to cause respiratory distress such as 
hypersensitivity pneumonitis (HP), allergic rhinitis and asthma exacerbations, the relationship between 
mold exposure and clinical outcomes remain unclear, and as a result MRI remains a contentious 
diagnosis [1,3]. Presently, there are three accepted pathophysiological mechanisms in mold induced 
disease. These mechanisms include: (a) infection by the organism, (b) generation of a deleterious 
immune response (e.g., allergy or HP), and c) toxic-irritant effects from mold metabolites (e.g., 
mycelial components, mycotoxins, or volatile organic compounds) [7–9].  
Occupants of mold-contaminated environments, particularly water-damaged buildings, develop 
symptoms that involve multiple organs and systems including the central nervous system (CNS) and 
the immune system in addition to pulmonary diseases, allergy, and inflammatory reactions [10–13]. 
Immunological dysfunction has been proposed by those who have demonstrated immunological 
changes in patients after mold exposure [14]. These changes include elevations of IgG, IgM, IgA, and 
IgE in addition to increased CD3, CD4, CD8, CD20, and decreased CD56. An accepted practice to 
evaluate allergic responses is the measurement of specific IgE to molds [15,16]. Mold-specific IgG has 
been primarily utilized in the evaluation of those with HP or allergic bronchopulmonary aspergillosis 
(ABPA), although immunoprecipitation remains the standard test for these diseases [8]. IgG antibodies 
directed to molds can be useful indicators of exposure [17,18]. In contrast, the majority of studies 
performed in different countries found similar symptom profiles in correlation with contaminated 
buildings [19]. The objective of this study was to evaluate the signs, symptoms, serum immunologic 
markers including IgG, IgA, and IgE (the latter via skin testing), mold specific peripheral blood 
mononuclear cells (PBMC) proliferative responses, and serum macrocyclic trichothecene levels in 
individuals complaining of mold related symptoms. 
2. Results and Discussion  
A total of 33 patients were evaluated. Sixteen patients (48%) were male and 17 were female (52%). 
Their ages ranged from 10 to 57 years. The demographic characteristics are summarized in Table 1. 
The patients reported that sites of exposure were home (88%), school (3%), and work (9%). Twenty-
one percent (7/33) had a previous history of asthma and 18% (6/33) had a previous history of allergic 
rhinitis. Seventy percent (23/33) had pets in the home and 45% (15/33) were exposed to environmental 
tobacco smoke. The presenting symptoms (Table 2) in order of predominance were rhinitis (82%), 
respiratory symptoms (73%), cough (58%), ocular pruritus (52%), gastrointestinal symptoms (48%), 
headache (42%), fatigue (36%), and central nervous system symptoms (30%). Thirty-seven percent of 
those studied had abnormal physical exam findings that included pale nasal mucosa and pharyngeal 
“cobblestoning”. Int. J. Mol. Sci. 2009, 10                 
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Seventy percent (23/33) of the patients had immediate wheal and flare skin reactivity to molds 
(Table 3). Thirty-three percent (11/33) were positive to mold via intradermal testing only. Nine percent 
(3/33) were positive only to environmental allergens; including tree, grass, ragweed, mites, cat and 
dog. Seventy-nine percent (26/33) were positive to at least one of the above mentioned antigens. 
Table 1. Demographic Characteristics of Patients Reviewed (n = 33). 
Characteristics  Children 
(n = 7) 
Adults 
(n = 26) 
Total 
(n = 33) 
Gender      
     Male  4 (57%)  12 (46%)  16 (48%) 
     Female  3 (43%)  14 (54%)  17 (52%) 
Age, mean (range), y  13 (10–17) 41 (18–57)  35 (10–57) 
Past medical history      
     Asthma  0 (0%)  7 (27%)  7 (21%) 
     Allergic rhinitis*  1 (14%)  5 (19%)  6 (18%) 
Mold exposure site**      
     Home  7 (100%)  22 (85%)  29 (88%) 
     School  0 (0%)  1 (4%)  1 (3%) 
     Work/Office  0 (0%)  3 (11%)  3 (9%) 
Social history      
     Smoke exposure***  3 (43%)  12 (46%)  15 (45%) 
     Pets exposure****  17 (65%)  6 (86%)  23 (70%) 
* A previous physician diagnosed allergic rhinitis and this was reported at our 
initial visit. 
** Location where exposure took place, data originated from the uniform 
questionnaire reported by patients. 
*** Patients are smokers or there is second hand smoke exposure.  
**** Patients own pets and are exposed on a regular basis.  
Table 2. Common Presenting Symptoms of Patients with Mold Exposure. 
Symptoms  Children 
(n = 7) 
Adults 
(n = 26) 
Total 
(n = 33) 
Rhinitis  7 (100%)  20 (77%)  27 (82%) 
Cough  5 (71%)  14 (54%)  19 (58%) 
Headache  3 (43%)  11 (42%)  14 (42%) 
Respiratory symptoms*  4 (57%)  20 (77%)  24 (73%) 
Ocular pruritus  5 (71%)  12 (46%)  17 (52%) 
CNS symptoms**  0 (0%)  10 (38%)  10 (30%) 
Fatigue  0 (0%)  12 (46%)  12 (36%) 
Gastrointestinal symptoms***    3 (43%)  13 (50%)  16 (48%) 
Epistaxis  0 (0%)  1 (4%)  1 (3%) 
Dysuria  0 (0%)  4 (15%)  4 (12%) 
* Symptoms include dyspnea, wheeze, chest tightness, and shortness of breath. 
** Symptoms include dizziness, anxiety, weakness, memory loss, and shaking. 
*** Symptoms include nausea, vomiting, and abdominal pain. Int. J. Mol. Sci. 2009, 10                 
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Table 3. Mold Panel for Skin Prick Test (SPT) and Intradermal Testing (ITD)*. 
Mold Antigens for IDT**    Mold Antigens for SPT**   
Mold Group I  13 (39%)  Alternaria 8(24%) 
    Aspergillus fumigatus  4(12%) 
    Aspergillus niger  0 (0%) 
    Botrytis cinerea  0 (0%) 
    Candida albicans  0 (0%) 
    Candida tropicalis  0 (0%) 
    Cephalosporium  0 (0%) 
    Cephalothecium roseum  0 (0%) 
Mold Group II  16 (48%)  Chaetomium globosum  0 (0%) 
    Cladosporium fulvum  0 (0%) 
    Curvularia spicifera  2 (6%) 
    Epicoccum nigrum  2 (6%) 
    Fusarium oxysporum  2 (6%) 
    Geotrichum candidum  0 (0%) 
    Cliocladium fimbriatum  0 (0%) 
    Helminthosporium  1 (3%) 
Mold Group III  16 (48%)  Hormodendrum  4 (12%) 
    Microsporum audouinii  0 (0%) 
    Microporum canis  0 (0%) 
    Mucor racemosus  0 (0%) 
    Neurospora intermedia  1 (3%) 
    Nigrospora oryzae  2 (6%) 
    Paecilomyces variotii  1 (3%) 
    Papularia montagnei  0 (0%) 
Mold Group IV  11 (33%)  Penicillium notatum  2 (6%) 
    Phoma destructive  1 (3%) 
    Pullularia pullulans  1 (3%) 
    Rhizopus stolonifer  1 (3%) 
    Rhodotorula rubra  1 (3%) 
    Saccharomyces  0 (0%) 
    Scopulariopsis  0 (0%) 
    Spondylocladium  1 (3%) 
Mold Group V  6 (18%)  Sporotrichum  1  (3%) 
    Stachybotrys chartarum  1 (3%) 
    Stemphylium herbarum  2 (6%) 
    Phycomyces  0 (0%) 
    Syncephalastrum  0 (0%) 
    Tetracoccosporium  0 (0%) 
    Trichoderma rufa  1 (3%) 
    Trichophyton rubrum  1 (3%) 
Total  19 (58%)    13 (39%) 
Controls    Negative Control  0 (0%) 
    Histamine  33 (100%) 
* Grouped antigens (eight per group) for intradermal testing (IDT) were divided alphabetically as 
provided by the extract manufacturer. 23 (70%) of the total symptomatic population was IPT and/or 
IDT positive. 
** Individuals from the symptomatic group were frequently positive for more than one mold 
antigen and mold group. Int. J. Mol. Sci. 2009, 10                 
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The mold surveys performed in patients’ homes reported Chaetomyces (18%), Acrosporium (15%), 
Stachybotrys (39%), Aspergillus (55%), Acremonium (6%), Scopulariopsis (9%), Rhodotorula (9%), 
Cladosporium (30%), Aureobasidium (6%), Penicillium (30%), Epicoccum (6%), Phoma (3%), and 
Alternaria (6%). 
The SDS-PAGE profiles of all the antigens prepared from the molds showed the presence of protein 
bands. Some mold extracts presented few bands (e.g., Trichoderma), while others presented more than 
ten (e.g., Alternaria alternata and A. ochraceous) (Figure 1). 
Figure 1. SDS-PAGE gel was loaded with 15 μg of protein per lane of A. fumigatus (2), A. 
versicolor (3), A. terreus (4), A. flavus (5),  Penicillium notatum (6), Stachybotrys 
chartarum (7), Trichoderma (8), Alternaria alternata (9), A. ochraceus (10), and 
Cladosporium herbarum (11). Molecular weight standard as indicated by MW and growth 
medium (1).  
 
Our study evaluated serum mold-IgG, -IgA, and -IgE antibodies (the latter via skin testing) as 
particular mold exposure markers. Thus, sera of all individuals were tested for mold specific-IgG and  
-IgA levels by ELISA and expressed as mean and SEM. Serum A. ochraceus- and A. terreus-IgG 
levels were shown to be significantly higher in symptomatic individuals compared to non-symptomatic 
individuals (p = 0.011 and p = 0.006 respectively). Conversely, serum Cladosporium herbarum- and 
Trichoderma-IgG levels were found to be significantly lower in symptomatic patients than in normal 
controls (p = 0.024 and p = 0.020 respectively). The remaining mold extracts-IgG levels were not 
significantly different between symptomatic and non-symptomatic groups (Figure 2). 
IgA levels are displayed in Figure 3. Higher serum Fusarium-IgA levels were present for both 
symptomatic and non-symptomatic populations (1.719 and 1.588 OD490 values respectively in diluted 
1:100 serum) without reaching statistical difference among the groups. Unexpectedly, serum 
Stachybotrys chartarum-IgA levels were significantly higher (p < 0.049) among the non-symptomatic 
population than in those with mold related symptoms. The remaining mold-IgA OD490 values obtained 
with sera diluted 1:100 showed lower values and no statistical difference between groups. 
 Int. J. Mol. Sci. 2009, 10                 
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Figure 2. Comparison of levels of specific IgG antibodies to mold antigens, as determined 
using ELISA. For each sample, the same amount of coated extract was used. All sera were 
diluted 1:100, and all reactions were stopped simultaneously. The results are presented as 
mean and standard error of OD490 values. The */+ symbols represent statistical differences 
between groups, *p < 0.05, **p < 0.01 symptomatic vs. non-symptomatic; +p < 0.05   
non-symptomatic vs. symptomatic groups. 
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Figure 3. Levels of specific IgA antibodies to mold antigens are presented as OD490 
values. Data are presented as mean ± SEM. The “p” value designated as +non-symptomatic 
vs. symptomatic < 0.05. 
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Mold extract induced stimulation of PBMC was investigated in symptomatic patients with 
suspected mold induced illness. Figure 4 shows the degree of stimulation of PBMC to different fungal 
antigens by the symptomatic individuals. Patients with mold related complaints reacted to 
Trichoderma (82% vs. 76% of non-symptomatic individuals), Alternaria  alternata (55% vs. 41%;  
p < 0.05), Cladosporium herbarum (42% vs. 12%; p < 0.05), Stachybotrys chartarum (27% vs. 17%;  
p < 0.05), A. versicolor (21% vs. below detectable limits; p < 0.05) and A. flavus (12% vs. below 
detectable limits; p < 0.05). Both non-symptomatic and symptomatic individuals specifically reacted to 
Fusarium with high prevalence (65% and 58%, respectively). 
Figure 4.  Proliferative responses of PBMC from symptomatic (filled bars) and non-
symptomatic (clear bars) populations. Results are given as percent of reactive individuals 
to diverse mold antigens after in vitro stimulation. Chi-square analysis was performed to 
assess percent data; asterisks represent “p” value < 0.05. 
 
 
 
Lastly, the presence of trichothecene mycotoxin from S. chartarum was determined in sera from 
symptomatic and non-symptomatic individuals. The sera levels of trichothecene, determined by 
competitive ELISA in OD450 values and percentages of inhibition, did not show any significant 
difference between the symptomatic individuals compared to the non-symptomatic population (data 
not shown). 
Although the potential of different molds or fragments to cause or aggravate adverse health effects 
remains unclear, the complaints associated with mold exposure continue to cause public and medical 
concern [6]. Mold is a greater hazard for persons with impaired host defenses or those with existing 
respiratory problems such as asthma and mold allergies. In recent years, a group of intermittent 
symptoms has been reported by individuals in connection to mold exposure [1,7,20–22]. 
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In the present study we evaluated 33 individuals aged 10–57 years with rhinitis, cough, other 
respiratory symptoms, ocular pruritus, gastrointestinal symptoms, headache, fatigue, and central 
nervous system symptoms that were attributable to mold exposure. While abnormalities were found in 
the clinical examination of 37% of symptomatic individuals, the patients with mold related health 
complaints did not show statistical significance in the humoral immune responses. IgE-mediated 
responses were determined by SPT and IDT to identify the causative mold allergens in the exposed 
individuals. Seventy percent of the symptomatic population (Table 3) had an immediate wheal and 
flare reaction to molds tested by SPT and IDT. 
Our group recently studied patients presenting to an allergy and asthma center with the chief 
complaint of “toxic mold exposure”. The symptoms included rhinitis, cough, headache, respiratory 
symptoms, CNS symptoms, and fatigue. The physical examination revealed pale nasal mucosa, and 
rhinorrhea. Fifty-three percent of the patients had skin reactions to molds. Allergic, rather than toxic, 
responses seemed to be the major cause of symptoms in the studied group [2]. Khalili et al., described 
the clinical characteristics of 50 patients with complaints of illness attributed to mold exposure in the 
home or workplace [1]. There was no consistent set of symptoms among patients having an average of 
more than eight symptoms; most patients reported a family or personal history of allergy or asthma. 
Three quarters of the patients had abnormal physical examination results, with inflammation of the eye 
or skin and congestion. The authors concluded that the majority of people examined had allergic 
reactions, not reactions to toxins [1].  
Measurements of anti-IgG -IgE and -IgA antibodies had been used to evaluate mold exposure in 
patients with hypersensitivity symptoms. In our study, mold-IgE measurements via skin testing was 
found to be positive in 70% of the symptomatic individuals, while only A. ochraceous- and A. terreus-
IgG levels were determined significantly higher in the symptomatic population. A study showed that 
mold-IgG antibodies and mold exposure could not be correlated in children attending moisture mold-
damaged schools, but their allergic conditions were associated with IgG antibodies to the molds [23]. 
Contrary to our findings, another study showed that serum IgA levels against S. chartarum of patients 
with asthma or mycotoxicosis were significantly increased compared to normal controls or 
asymptomatic groups, while IgG levels showed slight enhancement. IgE levels did not differ among 
the three groups of subjects examined [24]. 
In this study, although 39% of the surveyed homes reported the presence of Stachybotrys (informed 
by different evaluators), the levels of trichothecenes in sera were not significantly different from the 
non-symptomatic individuals. It is possible that the subjects in this study were never exposed to 
macrocyclic trichothecenes mycotoxins by any route or that some individuals had macrocyclic 
trichothecenes mycotoxins in their sera, but the level of free toxin quickly decreased below the 
detection limit. As Yike et al., have shown, macrocyclic trichothecene mycotoxins rapidly bind to 
serum albumin and are quickly removed from the blood stream [25]. Brasel et al., found no difference 
in trichothecene levels in sera of individuals with reported indoor mold exposure that was not specific 
for S. chartarum. Conversely, serum from individuals with documented indoor Stachybotrys exposure 
showed significantly higher levels of serum trichothecene [26]. Recently trichothecenes has been 
effectively detected in human tissue and body fluids samples, such as urine, sputum from patients 
exposed to mycotoxin producing molds in the environment [27]. Int. J. Mol. Sci. 2009, 10                 
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We recognize that our study is limited by different factors. First, the lack of mold extract 
standardization, as molds are highly responsive toward their growth environment. We have used both 
commercial mold extracts and culture filtrates from formalin-killed growths prepared in our 
laboratory, preparations that could considerably change their reactivity potential. The potency of the 
used extracts may be different since the final extract is highly dependent on how the molds grow. In 
addition, most of the commercial extracts are made of mycelia, yet human clinical symptoms are 
caused by spore inhalation. And finally, we also are aware that evaluation of mold sensitivity is 
difficult due to cross-reactivity between diverse molds compositions and protein structures [28–30]. In 
this study three symptomatic individuals appeared to be atopic, i.e. had skin reactions to allergens, but 
only to non-mold ones and another four patients did not appear to be atopic at least by skin testing. Yet 
unable to establish direct association between mold related complains and immunological evaluations, 
we could detect positive skin test to molds in 70% of the symptomatic individuals. 
3. Experimental Section 
We evaluated 33 patients who presented to the Asthma and Allergy Center at the Medical College 
of Wisconsin with complaints related to mold exposure. Non-symptomatic patients were normal 
volunteer subjects (n = 17) that had no history of detected mold incursion in their environments nor 
did they have any symptoms related to atopy (asthma or rhinitis). This study was approved by the 
human rights review committee of the Children’s Health System, Milwaukee, WI. Written informed 
consent was obtained from all participants. We evaluated symptoms, medical history, medication, 
family history, social history, and physical examination findings. A uniform questionnaire regarding 
mold exposure in the home, school, or work environment was reviewed. Mold surveys performed by 
various environmental analyses were assessed. Allergy skin prick testing (SPT) was performed on all 
patients followed by intradermal testing (IDT) when appropriate. Adults were tested with 39 mold 
extracts in 1:20 dilutions by SPT and five IDTs composed of mixtures of eight antigens each in 1:500 
dilutions of the mold allergens. Mold mixtures in IDT provide good information while avoiding 
performing 40 separate IDTs to detect IgE to molds. The IDTs were performed in the event of a 
negative SPT. Irritant reactions following IDTs were not noted. Children were tested with 8–15 
selected molds via SPT and when feasible via IDTs. Additional testing included ragweed, tree, grass, 
mite, dog, and cat allergen sensitivity. A positive SPT was defined as a wheal diameter three 
millimeters greater than the negative control. Mold extracts (Greer Laboratories, Lenior, LC) were 
administered using the Quintip skin test device (Hollister-Stier Laboratories LLC, Spokane, WA) for 
SPTs and via 27 gauge needles using separate syringes for IDTs. The asymptomatic group (n = 17) 
was composed of individuals exposed only to ambient mold levels and without clinical symptoms, and 
their living environments had no evidence of mold amplification. 
The fungal cultures were carried out using a modified method of the one previously described [31]. 
Briefly, A. versicolor (ATCC 9577), A. fumigatus (ATCC 42202), A. terreus (ATCC 1012), A. flavus 
(ATCC MYA-3631), Stachybotrys chartarum (ATCC 9182), Cladosporium herbarum (ATCC 28987), 
Penicillium notatum (ATCC 9179), Alternaria alternata (ATCC 6663), A. ochraceous, Trichoderma 
spp., and Fusarium spp., (the three former were isolated in our laboratory) spores were grown in 1:1 
mixture of synthetic broth AOAC (Difco, Detroit, MI), and Czapek-Dox broth (Difco), with added Int. J. Mol. Sci. 2009, 10                 
 
 
5480
glucose (1% w/v). Initially the cultures were rotated at 1,500 rpm for 24–48 hours at 37 °C. Ten 
milliliters of the culture were used as inocula for new stationary cultures, which were incubated for 
four weeks at room temperature in the same medium in one liter flasks. The culture filtrates from 
formalin-killed growths were passed through a filter paper (No. 1 Whatman Inc, Florham Park, NJ), 
and dialyzed against distilled water using 1,000 molecular weight cut off Spectra/Por Membrane 
(Spectrum Lab, Rancho Dominguez, CA) with three changes. A final filtration was performed for each 
dialyzed culture filtrate using a 0.45 micron Millipore filter. The filtrate was then freeze dried and 
stored (−70 °C). No attempt was made to inhibit or limit proteolysis during the preparation process. 
All extracts were assayed for protein by BCA protein assay kit (Pierce, Rockford, IL) according to 
manufacturer’s instruction. Extracts were also evaluated using sodium dodecyl sulphate (SDS) 
polyacrylamide gel electrophoresis (SDS-PAGE). Each mold extract was reduced in sample buffer 
(0.05 M Tris-HCl of pH6.8 with 1% SDS, 0.01% bromophenol blue, and 5% 2-β-mercaptoethanol), 
placed in a boiling water bath for five minutes, and applied at 15 μg of protein per lane on a stacking 
gel. Electrophoresis was carried out at constant current of 200 volts for one hour. The gels were 
stained with Coomassie Blue stain reagent (GelCode, Pierce, Rockford, IL). 
Sera of all studied individuals were used to determine mold specific IgG and IgA antibody levels by 
enzyme linked immunosorbent assay (ELISA) as reported [32].  Blanks included buffer without 
antigen, sera were run in duplicate, and all
 controls were included in each assay. The blanks were 
subtracted and the optical density values (OD490) expressed as mean and standard error (SE) [32]. 
PBMC were isolated on Hystopaque (Sigma, St Louis, MO) by gradient centrifugation and washed 
twice with Hank’s balanced salt solution (Invitrogen). Cells were counted and resuspended in 
supplemented RPMI medium (RPMI-1640 containing glutamine, sodium pyruvate, penicillin-
streptomycin, Invitrogen, Carlsbad, CA) [33]. Mold specific T cell proliferation was performed using 
isolated PBMC of all studied individuals. PBMC (1 × 10
5 were added in triplicate to the wells of a 
sterile microtiter plate containing 50, 12.5, and 3.13 μg/mL of the culture filtrate extracts from A. 
versicolor, A. ochraceous, A. fumigatus, A. terreus, A. flavus, Stachybotrys chartarum, Cladosporium 
herbarum, Penicillium notatum, Trichoderma, Alternaria alternata, and Fusarium. After 24 hours,  
20 μL of heat-inactivated fetal bovine serum (10% FBS, Invitrogen) were added to the wells to reduce 
non-specific background. The cultures were incubated for seven days at 37 °C in a CO2 incubator. 
Lymphocyte proliferation was determined by [
3H]-thymidine incorporation during the final eight hours 
of culture by pulsing with one µCi of [
3H]-thymidine (Amersham Biosciences, Piscataway, N.J., 
USA). Incorporated radioactivity was measured on a liquid scintillation counter (Packard Instruments 
Co., Meriden, CT). Specific proliferation was defined as antigen stimulated PBMC with counts per 
minute (cpm) at least three times higher that their corresponding non-stimulated cultures. The results 
were expressed as the percentage of reactive individuals [33,34]. 
Sera samples were analyzed for trichothecenes using a macrocyclic trichothecene-specific ELISA 
as described before [26,27,35,36], using the QuantiTox Kit (EnviroLogix, Portland, Maine). This kit 
incorporates highly specific polyclonal antibodies for macrocyclic trichothecenes immobilized on 
polystyrene microtiter wells. Prior to analysis, serum samples were individually aliquotted (200 μL) 
into sterile 1.5 mL microcentrifuge tubes followed by the addition of 600 μL of HPLC-grade 
acetonitrile. Samples were allowed to sit at room temperature for 15 minutes after which they were 
mixed thoroughly using a vortex mixer. They were then centrifuged at 14,500 rpm for three minutes to Int. J. Mol. Sci. 2009, 10                 
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pellet the precipitated proteins. Supernatants were individually transferred into clean 1.5 mL glass 
vials. Each sample was evaporated to completion under a gentle stream of dry nitrogen and 
resuspended in 200 μL of pre-warmed sterile water. The warming aided in the resuspension of 
samples. From each extracted sample, 170 μL were mixed with 170 μL of horseradish-peroxidase-
conjugated satratoxin G in separate 1.5 mL microcentrifuge tubes. The tubes were vortexed to ensure 
proper mixing. All samples and controls were added to wells in triplicate. Wells were covered and 
incubated at room temperature on a plate rocker for 45 minutes after which wells were washed five 
times with PBS using an automatic plate washer. Wells were blotted dry on clean paper towels. 
Immediately, 100 μL of tetramethylbenzidine substrate solution was added to each well. This was 
allowed to incubate at room temperature under reduced lighting for 15 minutes. To stop the reaction, 
100 μL of 1N hydrochloric acid were added to each well. Wells were read at 450 nm using a microtiter 
plate reader. Data were expressed as mean and ± SEM of OD450 nm values and percentages of 
inhibition (PI). PI was derived from raw data and was based on patient samples compared with normal 
human serum control and a positive control sample spiked with Roridin A. Controls were run in 
parallel with test samples. The PI represents the degree of inhibition the test samples had on the 
capability of the satratoxin G-horseradish peroxidase (HRP) conjugate to bind to the immobilized 
antibody and was calculated using the following equation: PI = 100 × 1 – [(OD450 sample – 
background)/(OD450 control – background)].  
Differences between the means of groups were analyzed with Microsoft Excel and Minitab for 
Windows programs. The two tails student t-test was used assuming unequal variances to compare 
levels of specific antibodies to mold antigens, while Chi-square analysis was performed to assess 
percent of reactive individuals to molds (proliferative responses); “p” values below 0.05 were 
considered significant. 
4. Conclusions 
The results of the present study suggest that the symptoms among mold exposed subjects, might be 
due to hypersensitivity to molds or mediated by some other immune or non-immune mechanisms. 
However, additional experimentation needs to be performed to clarify this relationship. 
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